(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 9.94% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Alpha Teknova's revenue in 2025 is $39,801,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2025 to be $2,198,014,943, with the lowest TKNO revenue forecast at $2,080,678,993, and the highest TKNO revenue forecast at $2,280,824,575. On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,429,153,916, with the lowest TKNO revenue forecast at $2,284,089,855, and the highest TKNO revenue forecast at $2,596,700,231.
In 2027, TKNO is forecast to generate $2,885,543,654 in revenue, with the lowest revenue forecast at $2,628,175,385 and the highest revenue forecast at $3,085,689,235.